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Background: State of the art sedation concepts on intensive care units (ICU) favor propofol for a time period of up
to 72 h and midazolam for long-term sedation. However, intravenous sedation is associated with complications
such as development of tolerance, insufficient sedation quality, gastrointestinal paralysis, and withdrawal symptoms
including cognitive deficits. Therefore, we aimed to investigate whether sevoflurane as a volatile anesthetic
technically implemented by the anesthetic-conserving device (ACD) may provide advantages regarding ‘weaning
time’, efficiency, and patient’s safety when compared to standard intravenous sedation employing propofol.
Method/Design: This currently ongoing trial is designed as a two-armed, monocentric, randomized prospective
phase II study including intubated intensive care patients with an expected necessity for sedation exceeding 48 h.
Patients are randomly assigned to either receive intravenous sedation with propofol or sevoflurane employing the
ACD. Primary endpoint is the comparison of the ‘weaning time’ defined as the time required from discontinuation
of the sedating agent until sufficient spontaneous breathing occurs. Moreover, sedation depth evaluated by
Richmond Agitation Sedation Scale and parameters of patient’s safety (that is, vital signs, laboratory monitoring of
organ function) as well as the duration of mechanical ventilation and overall stay on the ICU are analyzed and
compared. An intention-to-treat analysis will be carried out with all patients for whom it will be possible to define a
wake-up time. In addition, a per-protocol analysis is envisaged. Completion of patient recruitment is expected by
the end of 2012.
Discussion: This clinical study is designed to evaluate the impact of sevoflurane during long-term sedation of
critically ill patients on ‘weaning time’, efficiency, and patient’s safety compared to the standard intravenous
sedation concept employing propofol.
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Present guidelines for analgosedation on intensive care
units (ICU) of the Society of Critical Care Medicine
(SCCM) as well as the German Society for Anaesthesi-
ology and Intensive Care Medicine (DGAI) currently favor
intravenous sedation concepts employing propofol for
sedation up to 72 h and midazolam for long-term sedation
[1]. However, application of either substance is associated
with serious adverse effects such as the negative influence
of propofol on hemodynamics or propofol infusion syn-
drome as well as ceiling effects or the risk of accumulation
with incalculably prolonged wake-up times related to
long-term use of benzodiazepines, respectively [2-5].
The clinical implementation of volatile anesthetics for
long-term sedation of specific patients on intensive care
units has already been reported in the late 1980s. In par-
ticular, benefit from inhalative sedation was initially sug-
gested for patients with bronchial asthma or those
requiring the combination of a variety of hypnotics and
analgesics for adequate analgosedation (that is, patients
with drug abuse or addiction syndromes) [6]. Indeed,
volatile anesthetics provide the advantage of safe sed-
ation at the same time as increased controllability com-
pared to most intravenous sedation agents as they lack
accumulation or tolerance development. In this regard,
previous studies provide evidence for essentially shorter
and more predictable wake-up times of patients sedated
by inhalation compared to those sedated by propofol [7].
While a reduction in the time needed for the recovery of
alertness and sufficient spontaneous breathing allows for
immediate evaluation of neurological status, it also
reduces the time of mechanical ventilation and
ventilation-associated complications thus leading to a
shorter duration of the requirement for treatment of
patients on the ICU [8-12]. Moreover, volatile anes-
thetics such as sevoflurane itself have been shown to
exert organ protective, that is cardioprotective effects,
which render patients with cardiovascular disease specif-
ically eligible for potential benefit from sedation by inha-
lative agents [13,14].
As the application of volatile anesthetics requires a
classical vaporizer combined with a ventilation device or
the use of specifically designed so-called ‘closed
anesthesia systems’, inhalative sedation was mainly
restricted to operation rooms and thus not applicable on
intensive care units so far. However, with the invention
of the anesthetic-conserving device (ACD, AnaConDaW,
Sedana Medical, Uppsala, Sweden), a technical device
has become available which enables safe application in
clinical daily routine on the ICU by providing imple-
mentable size of the device itself at the same time as
avoidance of ambient air contamination [8,9,11]. Due to
their physicochemical characteristics, only sevoflurane
and isoflurane can be applied as volatile anesthetics withthe AnaConDaW system. Because of their low vapor
pressure, the use of a specific vapor is not required and
both isoflurane and sevoflurane can be mixed in their li-
quid aggregation state into the breathing gas via a perfu-
sor integrated in the ACD.
In the present study, we aimed to compare the stand-
ard use of intravenous sedation with propofol with inha-
lative sedation employing sevoflurane applied by the
ACD in mechanically ventilated patients requiring sed-
ation for longer than 48 h on the ICU. Primary endpoint
in this currently ongoing, two-armed, monocentric ran-
domized prospective phase II study is the time required
to re-establish sufficient spontaneous breathing and
extubation following discontinuation of the sedative
medication. Moreover, parameters such as sedation
depth, changes in hemodynamic and chemical laboratory
parameters, overall ventilation time and frequency of
ventilator-associated pneumonia, myocardial ischemia as
well as the overall duration of the ICU stay and the
related process costs are closely monitored, analyzed,
and compared. The results derived from this trial may
therefore help to dissect the future perspectives of inha-
lative long-term sedation with volatile anesthetics such
as sevoflurane with respect to efficiency and patient’s
safety on intensive care units.
Method
Study design
The trial was designed as a two-armed, monocentric,
randomized prospective phase II study for long-term
(that is, >48 h) sedation of intensive care patients. A
novel sedation regime employing sevoflurane applied by
inhalation is compared to the commonly used intraven-
ous procedures with propofol that are in accordance
with current guidelines for sedation of intensive care
patients.
Patient characteristics
Eligibility of patients was verified in accordance to the
inclusion and exclusion criteria given below. Having
obtained informed written consent of the patient or the
patient’s legal representative for participation in the clin-
ical trial, randomization and allocation to a therapy
group is carried out.
Inclusion criteria
– Intubated patients with expected necessity for long-
term sedation > 48 h
– Age ≥ 18 years
– Signed declaration of consent by the patient or a
legal representative
– Continuous mechanical ventilation for less than
48 h by the time of recruitment
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– No indication for sedation
– Pregnancy and breastfeeding
– Acute pulmonary failure
– Existent severe liver failure
– Primary poor prognosis
– Participation in another study during the previous
30 days
– Contraindications against the study medication
Interventions to be evaluated
Following assurance of eligibility according to the inclu-
sion and exclusion criteria, patients are randomly
assigned to either the intervention group to receive
sevoflurane using the ACD (Group S) or the control
group receiving propofol followed by midazolam on day
4 (Group P). A flowchart of the study is depicted in
Figure 1.
Monitoring of sedation
Patients of group S are sedated by continuous applica-
tion of sevoflurane employing the anesthetic-conserving
device (ACD, AnaConDaW, Sedana Medical, Sweden).
This anesthesia gas-recirculation-system consists of a
miniature vaporizer integrated into the ventilation hose
system between the Y-piece and the patient, thereby re-
placing conventional ventilation filters (Figure 2). In
addition to a conventional heat and moisture exchangeFigure 1 Flowchart of the study set-up.(HME) filter, the miniature vaporizer comprises a
lipophilic-activated carbon particle filter absorbing the
majority of exhaled anesthetic condenses. The system-
specific ‘dead space’ is 100 mL. The detailed functional
principle of the system has already been described in de-
tail [15-18].
Based on current guidelines, sedation of patients in
group P is initially conducted by intravenous application
of propofol (Disoprivan 2%). On the 4th day of sedation,
propofol is changed to midazolam in order to avoid pro-
pofol infusion syndrome. To ensure adequate analgetic
co-regimes, both study groups are subjected to continu-
ous application of remifentanil or sufentanil.
Sedation depth is monitored by determination of to
the Richmond-Agitation-Sedation Scale (RASS) (pursu-
ing a target score value of −3 or −4) every second hour
as well as continuous monitoring of the Bispectral Index
(BIS) and the Cerebral State Index (CSI) aiming for
index values of 40 ± 10.
During sedation, all vital parameters including blood
pressure, heart rate, temperature, and pulsoximetry are
continuously monitored and calibration of the respirator
is ensured. In patients with severe neurological damage,
intracranial pressure (intraparenchymal tube, external li-
quor drainage) and cerebral perfusion pressure are add-
itionally monitored. Arterial blood gas analysis is
performed every 4 h in order to exclude significant
deviations in acid–base metabolism, electrolyte balance,
or levels of blood glucose. Laboratory parameters such
Figure 2 The anesthetic-conserving device (AnaConDaW) in the
clinical set-up.
Soukup et al. Trials 2012, 13:135 Page 4 of 7
http://www.trialsjournal.com/content/13/1/135as blood counts, hemostasis, parameters of infection, as
well as indicators of hepatic and renal function are ana-
lyzed on a daily basis. In addition, serum levels of fluor-
ide, cortisol, ACTH, and Troponin I are determined
(Figure 1).Duration of study
The observation period of the study lasts until 3 days
after extubation or when spontaneous breathing is per-
sistent via tracheostomy. The planned overall duration
of the clinical trial will be 24 months.Primary endpoint
Primary endpoint of the study is the time required from
discontinuation of application of the sedating agent (that
is, sevoflurane or propofol) until extubation or persistent
spontaneous breathing is possible via tracheostomy
(‘weaning time’).
In this regard, the following events in the wake-up
phase are documented in order of appearance:
O Opening of eyes
O Ability to exert purposive motor function
O Achievement of the ability to cooperate, that is to
follow instructions
O Beginning of spontaneous breathing and subsequent
extubationSecondary endpoints
Evaluation of sedation quality
Secondary endpoint is the quality of sedation deter-
mined by the ratio of the targeted sedation depth to the
actual sedation depth measured by RAS-score. In group
S, the number of adjustments of exhalative sevoflurane
concentration is registered, while in group P the neces-
sity for supplementary bolus injections is enumerated.Safety
All vital signs such as blood pressure, heart rate, and
peripheral oxygen saturation (SpO2) are monitored con-
tinuously. Blood gas analyses are performed every
fourth hour and chemical laboratory parameters as
well as urea, creatinine, cystatin C, interleukin 6 and 8
(IL-6, IL-8), C-reactive protein (CRP), procalcitonin
(PCT), coagulation parameters, blood count, aspartate-
aminotransferase (ASAT), alanine-aminotransferase (ALAT),
gamma-glutamyl-transferase (GGT), bilirubin, and troponin
I are determined at least on a daily basis. The course of
adrenocorticotropic hormone (ACTH) and cortisol serum
levels is monitored by daily measurements in order to de-
tect the influence of the respective trial substance on the
neuroendocrine system.
Determination of fluoride concentrations in blood and
urine is performed in order to rule out substance-
associated effects on renal function. Also, Neutrophil
Gelatinase-Associated Lipocalin (NGAL) and urine pro-
teins (CRP, IL-6, IL-8, ß-1, and ß-2 microglobulin quan-
titatively) are also measured daily (Figure 1).
Moreover, criteria for patient safety including duration
of mechanical ventilation, incidence of ventilation-
associated pneumonia, newly developed myocardial is-
chemia, and frequency of acute renal failure are evalu-
ated separately for groups P and S. Finally, the length of
the overall stay on the ICU and the daily Simplified
Acute Physiology Score II (SAPS II) are documented for
each study patient.
Economical considerations
The costs of consumables and nursing per patient will
be documented by means of the LEPW nursing interven-
tion and workload measurement system.
Statistical methods
Estimation of sample size
Calculations of sample size for the propofol group
(group P) are based on the assumption of a median
weaning time of 132 ± 258 min following long-term sed-
ation in ICU patients with propofol as previously
described [19]. Regarding the sevoflurane group (group
S), unpublished observations from 14 intensive care
patients in our clinic revealed a median weaning time of
22.8 ± 6.7 min. Thus, a sample size of 47 patients per
group will be necessary for a two-armed t-test, a first
order error of α= 0.05, and a power of 80%. With re-
spect to a planned drop-out rate of 5%, the necessary
sample size will be 50 patients per group.
Final evaluation
An intention-to-treat analysis (ITT) will be carried out
as the standard evaluation method with all patients for
whom weaning time can be determined. In addition, a
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analyze those patients with unforeseeable changes of
sedation regimes compared to the regime they were ini-
tially randomized to.
The ITT analysis serves for the confirmatory decision-
making. In contrast, the peer protocol analysis is used to
describe the puristic substance-related effect and may
further help to separate the effects of each sedation
concept itself. However, this approach does not always
reflect the everyday clinical practice.
The time required from discontinuation of application
of the sedating agent (either sevoflurane or propofol)
until extubation or persistent spontaneous breathing via
tracheostomy (weaning time) will be analyzed employing
Student’s t-test or Mann–Whitney U-test for absence of
normal distribution, respectively. Moreover, the number
of assessments of actual sedation depth revealing the
identical sedation depth as pursued with reference to the
RAS score as well as ventilation time, length of ICU stay,
and the related costs will be compared. The two binary
secondary criteria, namely ventilation-associated pneu-
monia and myocardial ischemia, will be evaluated using
the chi-square test. All other secondary criteria will be
presented descriptively with respect to the time course
of each individual patients study period.
Ethical considerations
The trial has been registered in a public trials registry
(registry number ISRCTN 90609144). The trial will be
conducted according to the principles of good practice
(ICH-GCP) and the Data Protection Act 1998 and the
actual laws in Germany (German drug law, German data
protection law) [20,21]. The trial is sponsored by the
Martin-Luther University of Halle. The Trial Manage-
ment Group, through the Trial Steering Committee, will
ensure that adequate systems are in place for monitoring
the quality of the study (compliance with Good Clinical
Practice (GCP)) and expedited (when appropriate) and
routine reports of adverse effects.
The study protocol at hand has been positively
reviewed by the responsible ethics commission of the
Medical Faculty of the University Halle. This study pri-
marily recruits patients that are not able to give consent.
According to }41 (3) of the German Medicinal Products
Act (‘Arzneimittelgesetz’ AMG) ‘. . .the use of the investi-
gational medicinal product must be indicated, according
to the findings of medical science, in order to save the
life of the person concerned, to restore him or her to
health or to alleviate suffering. Furthermore, such re-
search must relate directly to a life-threatening or highly
debilitating clinical condition suffered by the person
concerned and the clinical trial may involve as little bur-
den and other foreseeable risks as possible for the per-
son concerned. Both the degree of burden and the riskthreshold must be defined specifically in the trial proto-
col and monitored constantly by the investigator. The
clinical trial may only be conducted if there is a justified
expectation that the benefits of using the investigational
medicinal product for the person concerned outweigh
the risks or that the use does not entail any risks. . .’
[22].
The AnaConDaW-system itself as well as the required
residue gas filters are CE-certified medical products.
These systems are currently in clinical use, though the
study situation is relatively limited in comparison to the
conventional concepts established to date. Sevoflurane is
a volatile hypnotic that is routinely used in anesthesia.
According to its technical information sheet pursuant to
} 11a AMG, the substance is suited for initiation and
preparation of inhalative anesthesia of grown-ups and
children, on an outpatient as well as inpatient basis. Pos-
sible problems result from the relatively sparse experi-
ence in long-term use. Therefore, this clinical study
brings together comprehensive daily laboratory evalua-
tions in order to detect clinically relevant side effects on
the heart, liver, and kidneys as soon as possible. Finally,
the results of the present study may help to provide evi-
dence regarding parameters related to patient safety and
the occurrence of adverse effects when sevoflurane and
propofol are compared and may thus support dissecting
the potential role of inhalative sedation concepts in the
future.
Initial results from the employment of the AnaCon-
DaW-system, particularly with isoflurane, have provided
evidence for shorter mechanical ventilation duration
[9,11,14] and organ-protective effects of sevoflurane
have been suggested [23,24]. In this regard, further
investigations on the long-term application of inhalative
anesthetics on intensive care units may help to emerge
novel sedation concepts employing these agents that
may thus possibly help to provide increased safety for
the patients cared for. Regarding a benefit-to-risk ana-
lysis, it may be estimated that the benefits of applying
sevoflurane may outweigh the possible risks (side effects)
and the prospects of conventional intravenous sedation
concepts.
The consent procedure comprises the practice of the
possibility of consent by a previously appointed legal
representative as well as the primary or ongoing consent
of the patient himself.
Discussion
It has already been shown in the late 1980s that the ap-
plication of isoflurane in intensive care treatment of cer-
tain groups of patients (that is, patients that are difficult
to sedate or with bronchial asthma) offers distinct
advantages compared to intravenous sedation [6,9].
Korth et al. examined 20 mechanically ventilated
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demonstrated that in addition to an improved sedation
quality and a reduction of bronchial spasticity there were
no clinically relevant changes in serum fluoride concen-
tration or other organ-related side effects [6]. In these
studies, the anesthesia gas was either applied via the
usual vapor in connection with a ventilation device
(Servo 900C) or by using a ‘closed anesthesia system’
(PhysioflexW, ZeusW, Dräger, Lübeck, Germany).
Because of the short availability of the system so
far, clinical experience with the AnaConDaW system is
currently limited with most studies referring to the
substance isoflurane. For example, Sakey et al. de-
monstrated that the time until extubation was distinctly
shorter after sedation with isoflurane compared to sed-
ation with midazolam following an application time up
to 96 h (isoflurane: 10 ± 5 min vs. midazolam: 250 ± 270
min) [9]. However, further improvement of the concept
of ‘inhalative sedation’ applied in critically ill patients
could be expected from application of sevoflurane as it
provides favorable pharmacokinetic as well as possibly
organ-protective effects [8,9,25].
Following inhalative application, 3% to 6% of sevoflur-
ane is metabolized and metabolic products such as fluor-
ide ions may exert toxic effects that have to be taken
into account considering long-term use of sevoflurane.
Although previous studies revealed an increase of the
measured fluoride concentration already shortly after
the beginning of application, evidence for clinical rele-
vance of fluoride ion exposition even after long-time ap-
plication of sevoflurane could not be provided [24,26].
Despite previous studies, the application of sevoflurane
for long-term sedation in critically ill patients regarding
patient safety and quality of sedation has not been inves-
tigated so far. As this group of patients confers signifi-
cant morbidity and mortality, strategies to improve the
quality of care and outcome of these patients is therefore
especially needed.
Conclusion
In conclusion, the present clinical study is powered to
test the hypothesis that sevoflurane is non-inferior to
conventional intravenous sedation with propofol in the
context of long-term sedation of critically ill patients
and moreover associated with a better sedation quality
without any detrimental side effects in this patient
population.
Trial status
The trial is currently ongoing; patient recruitment shall
be completed in 2012.
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